http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104262481-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 |
| filingDate | 2013-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104262481-B |
| titleOfInvention | A kind of preparation method and applications of the analog of extended GLP-1 1 of side chain modification |
| abstract | The invention discloses the analogs of GLP 1 to have general formula A： 7 HAEGT FX 13 SDV SSY X 20 E X 22 QAA X 26 EFIAW LVKGR G 37 Formula A, wherein, X 13 The lysine (K nX) modified for threonine or side chain, X 20 The lysine (K nX) modified for leucine or side chain, X 22 The lysine (K nX) modified for glycine or side chain, X 26 For lysine (the K NH of unprotected side chain modification 2 ) or side chain modification lysine (K nX)；X 13 、X 20 , X 22 And X 26 In have and only one be lysine K nX, wherein n=4~10, X be glycine, alanine or valine.The analogs of this GLP 1 can be effectively increased GLP 1 blood halflife, the present situation for overcoming it can not clinically be used because of half-life short, be had wide application prospects in diabetes, obesity treatment drugs field.The invention also discloses the preparation method and applications of the analogs of GLP 1. |
| priorityDate | 2013-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 118.